Transcode Therapeutics, Inc. — Investor Relations & Filings
Transcode Therapeutics, Inc. is a clinical-stage oncology company developing RNA-based therapeutics for metastatic cancer. The company's strategy focuses on the specific eradication of metastatic tumor cells by targeting microRNA-10b (miRNA-10b), identified as a master regulator of metastasis. Its lead therapeutic candidate, TTX-MC138, is an oligonucleotide designed to inhibit miRNA-10b. Transcode utilizes a proprietary iron oxide nanoparticle delivery platform, TTX, to transport its therapeutic candidates to tumor sites. Pre-clinical studies in murine models have demonstrated that TTX-MC138 can induce regression of established metastases in breast and pancreatic cancers. The company's approach has potential applicability across numerous cancer types where miRNA-10b is involved, including breast, pancreatic, ovarian, and colon cancers, as well as glioblastomas.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| S-3 - Transcode Therapeutics, Inc. (0001829635) (Filer) | 2026-04-30 | English | |
| 8-K - Transcode Therapeutics, Inc. (0001829635) (Filer) | 2026-04-07 | English | |
| 8-K - TRANSCODE THERAPEUTICS, INC. (0001829635) (Filer) | 2026-03-03 | English | |
| 8-K - Transcode Therapeutics, Inc. (0001829635) (Filer) | 2026-02-23 | English | |
| 8-K Filing | 2026-02-05 | English | |
| Major Shareholding Notification 2026 | 2026-01-07 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 39241455 | S-3 - Transcode Therapeutics, Inc. (0001829635) (Filer) | 2026-04-30 | English | ||
| 33708775 | 8-K - Transcode Therapeutics, Inc. (0001829635) (Filer) | 2026-04-07 | English | ||
| 32899329 | 8-K - TRANSCODE THERAPEUTICS, INC. (0001829635) (Filer) | 2026-03-03 | English | ||
| 32827319 | 8-K - Transcode Therapeutics, Inc. (0001829635) (Filer) | 2026-02-23 | English | ||
| 31953280 | 8-K Filing | 2026-02-05 | English | ||
| 13329328 | Major Shareholding Notification 2026 | 2026-01-07 | English | ||
| 13329327 | FORM 8-K | 2026-01-06 | English | ||
|
2025
8 filings
| |||||
| 13329329 | DEFA14A | 2025-12-23 | English | ||
| 13329332 | FORM 8-K/A | 2025-12-23 | English | ||
| 13329330 | Regulatory Filings 2025 | 2025-12-23 | English | ||
| 13329331 | OWNERSHIP DOCUMENT | 2025-12-22 | English | ||
| 13329333 | OWNERSHIP DOCUMENT | 2025-12-22 | English | ||
| 13329334 | FORM 8-K | 2025-12-22 | English | ||
| 13329335 | S-3 | 2025-12-12 | English | ||
| 13329336 | FORM 8-K | 2025-12-11 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Skye Bioscience, Inc.
Clinical-stage biotech developing treatments for obesity an…
|
SKYE | US | Professional, scientific and te… |
|
SLSBio(Specialty Lab Solution Bio) Co., Ltd
Offers lab services and manufactures diagnostics for the ph…
|
246250 | KR | Professional, scientific and te… |
|
SMO ClinPlus CO., LTD.
Provides clinical trial site management, CRC services, and …
|
301257 | CN | Professional, scientific and te… |
|
Soiken Holdings Inc.
Commercializes medical research via biomarker tech, clinica…
|
2385 | JP | Professional, scientific and te… |
|
Solid Biosciences Inc.
Develops gene therapies for rare neuromuscular and cardiac …
|
SLDB | US | Professional, scientific and te… |
|
Sona Nanotech Inc.
Develops and supplies proprietary gold nanorod technology f…
|
SONA | CA | Professional, scientific and te… |
|
SPARC TECHNOLOGIES LIMITED
Develops graphene technologies, green hydrogen, and sodium-…
|
SPN | AU | Professional, scientific and te… |
|
SpectraCure
Develops a minimally invasive treatment system for internal…
|
SPEC | SE | Professional, scientific and te… |
|
Sprint Bioscience
Develops and out-licenses preclinical oncology drug candida…
|
SPRINT | SE | Professional, scientific and te… |
|
SPRUCE BIOSCIENCES, INC.
A clinical-stage biopharma developing therapies for underse…
|
SPRB | US | Professional, scientific and te… |
Transcode Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35264/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35264 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35264 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35264 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35264}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Transcode Therapeutics, Inc. (id: 35264)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.